GVHD

Clinical investigators are currently exploring ustekinumab, an IL-12 and IL-23 antagonist, for graft vs host disease (GVHD) prophylaxis in matched unrelated donor hematopoietic cell transplantation (HCT) recipients. A phase 2 …

Russell NH, Hills RK, Thomas A, Thomas I, Kjeldsen L, Dennis M, et al. Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic …

Fred Hutch Cancer Center opened its doors 50 years ago, founded by the team that made bone marrow transplantation a reality. Since the breakthroughs in the late 1960s that showed the Nobel …

Patient characteristics Baseline characteristics of the study population are shown in Table 1. A total of 8,764 patients were included, of whom 7,725 (88%) received his rATG and 1,039 (12%) …